European Commission Approves AbbVie Boey Anti-Wrinkle Therapy

The European Commission has approved AbbVie's anti-wrinkle therapy Boey for the temporary improvement of glabellar lines ^[1].

This approval expands the availability of aesthetic medical treatments within the European Union, targeting the specific reduction of frown lines. The decision allows AbbVie's Allergan Aesthetics unit to bring the therapy to a broader market of patients seeking non-surgical cosmetic interventions.

Boey is designed to treat glabellar lines, the vertical creases that form between the eyebrows. These lines are often associated with frowning or concentrating and are a primary target for neuromodulator injections in aesthetic medicine.

The regulatory nod from the European Commission signifies that the therapy has met the necessary safety and efficacy standards required for use across the bloc ^[1]. By securing this approval, AbbVie strengthens its position in the competitive anti-aging market, where precision and temporary results are key drivers for consumer demand.

Allergan Aesthetics, the specific unit responsible for the development and distribution of the therapy, will now move toward commercial deployment. The process of integrating a new approved therapy into the EU market involves coordinating with healthcare providers, and ensuring compliance with regional medical guidelines.

While the European Commission provided the authorization on Friday, the specific timeline for the therapy's rollout to clinics across member states remains to be detailed ^[1].